T 1087/20 (RNA-directed target DNA modification/UC) du 06.11.2024

Identifiant européen de la jurisprudence: ECLI:EP:BA:2024:T108720.20241106
Date de la décision: 6 novembre 2024
Numéro de l'affaire: T 1087/20
Requête en révision de: -
Numéro de la demande: 13793997.1
Classe de la CIB: C12N 15/63 C07K 19/00 C12N 15/10 C12N 15/90 C12N 15/11
Langue de la procédure: Anglais
Distribution: Non distribuées (D)
Téléchargement: Décision en anglais
Versions JO: Aucun lien JO trouvé
Autres décisions pour cet affaire: -
Résumés pour cette décision: -
Titre de la demande: Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
Nom du demandeur: The Regents of the University of California
University of Vienna
Charpentier, Emmanuelle
Nom de l'opposant: Pohlman, Sandra M.
Griebling, Onno
TL Brand & Co Ltd
HGF Limited
Jones Day
Allergan Pharmaceuticals International Limited
Truscott, Glyn, John
Chambre: 3.3.08
Sommaire: -
Dispositions juridiques pertinentes: European Patent Convention Art 104(1)European Patent Convention Art 111(1)European Patent Convention Art 113(2)Rules of procedure of the Boards of Appeal 2020 Art 016(1)
Mots-clés: Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Apportionment of costs - (no)
Appellant may withdraw appeal any time unless abuse of procedure
Same principles apply to withdrawal consent to/approval of text of patent
Withdrawal of consent two weeks before oral proceedings, two months from communication with preliminary opinion, and in light of complexity of case - no abuse of procedure
Exergue: -
Affaires citées: T 0073/84 T 0186/84 T 0490/05 T 0301/12 T 1663/13 T 1714/14 T 0040/17 T 1310/19 T 1484/19 T 0635/21 T 1995/21
Affaires citantes: T 0617/20

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

3. The requests for a different apportionment of costs are rejected.